Lehrstuhl für Innere Medizin I (Medizin 1)

Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial (2022) Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, et al. Journal article Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study. (2022) Simon D, Tascilar K, Fagni F, Kleyer A, Krönke G, Meder C, Dietrich P, et al. Journal article CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease (2022) Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, et al. Journal article Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation (2022) Zundler S, Günther C, Kremer AE, Rothhammer V, Neurath M, Zaiss M Journal article, Review article Motorized spiral enteroscopy: Results of an international multicenter prospective observational clinical study in patients with normal and altered gastrointestinal anatomy (2022) Beyna T, Moreels T, Arvanitakis M, Pioche M, Saurin JC, May A, Knabe M, et al. Journal article Pig models for Duchenne muscular dystrophy – from disease mechanisms to validation of new diagnostic and therapeutic concepts (2022) Stirm M, Fonteyne LM, Shashikadze B, Stöckl JB, Kurome M, Keßler B, Zakhartchenko V, et al. Journal article, Review article A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis (2022) Peyrin-Biroulet L, Arkkila P, Armuzzi A, Atreya R, Danese S, Ferrante M, Guardiola J, et al. Conference contribution Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies (2022) Atreya R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, et al. Conference contribution Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study (2022) Bokemeyer B, Plachta-Danielzik S, Di Giuseppe R, Deppe H, Mohl W, Teich N, Hoffstadt M, et al. Conference contribution Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn's Disease and inadequate response to risankizumab maintenance therapy (2022) Baert FJ, Atreya R, Kakuta Y, Long M, Roblin X, Neimark E, Song A, et al. Conference contribution